glimepiride 3 MG Oral Tablet

Verify with CMS →

glimepiride

RxCUI: 153842

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0.3%
Plan Coverage
14
Plans Covering
T1.8
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for glimepiride 3 MG Oral Tablet

Per the CMS 2026 Part D formulary file, glimepiride 3 MG Oral Tablet (RxNorm concept RXCUI 153842, generic name glimepiride) appears on 6 distinct formulary files spanning 14 Medicare Part D plan offerings - 0.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 1.8.

Real-world access to glimepiride 3 MG Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 16.7% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,187,344 Part D beneficiaries filled glimepiride 3 MG Oral Tablet in 2023, with total plan-and-beneficiary spending of $62,964,614 and an average per-beneficiary annual cost of $53.03. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry glimepiride 3 MG Oral Tablet today.

Coverage Details

Formularies covering
6
Plans covering
14
Coverage rate
0.3%
Tier range
Tier 1 – Tier 6
Average tier
Tier 2, Generic

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
16.7% of formularies

2023 Medicare Spending

Beneficiaries
1,187,344
Total spending
$62,964,614
Avg per beneficiary
$53.03

Tier Distribution Across Plans

10 plans
Tier 1, Preferred Generic
4 plans
Tier 6, Select Care

Medicare Advantage Plans (MA-PD) Covering glimepiride 3 MG Oral Tablet

14 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Mass General Brigham Advantage (PPO) Mass General Brigham Health Plan, Inc. T1 No $0 MA
Mass General Brigham SCO (HMO D-SNP) MASS GENERAL BRIGHAM HEALTH PLAN, INC T1 No $0 MA
Mass General Brigham One Care (HMO D-SNP) MASS GENERAL BRIGHAM HEALTH PLAN, INC T1 No $0 MA
Leon MediExtra (HMO) LEON HEALTH, INC. T1 No $0 FL
Leon MediDual (HMO D-SNP) LEON HEALTH, INC. T1 No $0 FL
Leon MediMore (HMO) LEON HEALTH, INC. T1 No $0 FL
Leon MediMax (HMO D-SNP) LEON HEALTH, INC. T1 No $0 FL
Mass General Brigham Advantage Secure (HMO-POS) Mass General Brigham Health Plan, Inc. T1 No $62.00 MA
Mass General Brigham Advantage Premier (PPO) Mass General Brigham Health Plan, Inc. T1 No $79.70 MA
Mass General Brigham Advantage Signature (PPO) Mass General Brigham Health Plan, Inc. T1 No $147.20 MA
Aspire Health Protect (HMO) ASPIRE HEALTH PLAN T6 No $0 CA
Aspire Health Value (HMO) ASPIRE HEALTH PLAN T6 No $22.60 CA
Aspire Health Advantage (HMO) ASPIRE HEALTH PLAN T6 No $44.80 CA
Aspire Health Plus (HMO-POS) ASPIRE HEALTH PLAN T6 No $119.20 CA

Frequently Asked Questions

Is glimepiride 3 MG Oral Tablet covered by Medicare Part D?

Yes, glimepiride 3 MG Oral Tablet is covered by 14 Medicare Part D plans (0.3% of all Part D formularies).

What tier is glimepiride 3 MG Oral Tablet on Medicare Part D plans?

glimepiride 3 MG Oral Tablet averages Tier 1.8 across Part D plans, ranging from Tier 1 to Tier 6.

Does glimepiride 3 MG Oral Tablet require prior authorization?

0% of Part D formularies require prior authorization for glimepiride 3 MG Oral Tablet. Step therapy: 0%. Quantity limits: 16.7%.

How much does Medicare spend on glimepiride 3 MG Oral Tablet?

In 2023, total Medicare Part D spending on glimepiride 3 MG Oral Tablet was $62,964,614, covering 1,187,344 beneficiaries. The average spend per beneficiary was $53.03.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial